PYC Therapeutics has concluded the first cohort dosing of healthy volunteers in the Phase Ia single ascending dose (SAD) ...

Introduction & Market Context PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market ...

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased ...

PYC Therapeutics Ltd’s latest earnings call for the second quarter of 2025 highlighted the company’s strategic focus on pipeline development and potential asset monetization. Despite no specific ...

The last three months have been tough on PYC Therapeutics Limited (ASX:PYC) shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't change the fact that the ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has announced positive results from its ongoing clinical trials for VP-001, a treatment for the childhood blinding ...

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter PYC Therapeutics (ASX:PYC) is advancing its VP-001 drug candidate, aimed at treating Retinitis Pigmentosa ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

The secondary aim of the trial is to assess the drug’s efficacy when the trial extends to polycystic kidney disease patients in the second half of this year. Credit ...